VIM

Summary

VIM (vimentin, HGNC:12692) is a protein-coding gene on chromosome 10p13, encoding Vimentin (P08670). Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells.

This gene encodes a type III intermediate filament protein. Intermediate filaments, along with microtubules and actin microfilaments, make up the cytoskeleton. The encoded protein is responsible for maintaining cell shape and integrity of the cytoplasm, and stabilizing cytoskeletal interactions. This protein is involved in neuritogenesis and cholesterol transport and functions as an organizer of a number of other critical proteins involved in cell attachment, migration, and signaling. Bacterial and viral pathogens have been shown to attach to this protein on the host cell surface. Mutations in this gene are associated with congenital cataracts in human patients.

Source: NCBI Gene 7431 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cataract (Definitive, GenCC) — +2 more curated relationships
• GWAS associations: 6
• Clinical variants (ClinVar): 135 total — 1 likely-pathogenic
• Phenotypes (HPO): 5
• Druggable target: yes
• MANE Select transcript: NM_003380

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12692
Approved symbol	VIM
Name	vimentin
Location	10p13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000026025
Ensembl biotype	protein_coding
OMIM	193060
Entrez	7431

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 11 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000224237, ENST00000421459, ENST00000469543, ENST00000478746, ENST00000485947, ENST00000487938, ENST00000495528, ENST00000497849, ENST00000544301, ENST00000637053, ENST00000881961, ENST00000881962, ENST00000881963, ENST00000946784, ENST00000946785, ENST00000946786, ENST00000946787

RefSeq mRNA: 1 — MANE Select: NM_003380 NM_003380

CCDS: CCDS7120

Canonical transcript exons

ENST00000544301 — 10 exons

Exon	Start	End
ENSE00000692805	17233587	17233682
ENSE00000692812	17234693	17234818
ENSE00000815998	17236294	17236379
ENSE00001121153	17235846	17235889
ENSE00001270949	17235169	17235389
ENSE00001270958	17230650	17230710
ENSE00001942703	17228241	17228524
ENSE00002284410	17229276	17229985
ENSE00003614198	17233770	17233931
ENSE00003647967	17237230	17237593

Expression profiles

Bgee: expression breadth ubiquitous, 307 present calls, max score 99.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2467.6537 / max 125601.9960, expressed in 1738 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104054	2442.2995	1693
104057	7.6571	1454
104050	6.6265	1417
104073	5.2122	1240
104053	1.6280	818
104046	1.4872	412
104052	0.9798	522
104051	0.7548	191
205739	0.4312	189
104055	0.1770	84

Top tissues by expression

312 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	99.99	gold quality
descending thoracic aorta	UBERON:0002345	99.97	gold quality
right coronary artery	UBERON:0001625	99.96	gold quality
blood vessel layer	UBERON:0004797	99.96	gold quality
layer of synovial tissue	UBERON:0007616	99.96	gold quality
dorsal root ganglion	UBERON:0000044	99.95	gold quality
urethra	UBERON:0000057	99.95	gold quality
aorta	UBERON:0000947	99.95	gold quality
nerve	UBERON:0001021	99.95	gold quality
tibial nerve	UBERON:0001323	99.95	gold quality
ascending aorta	UBERON:0001496	99.95	gold quality
thoracic aorta	UBERON:0001515	99.95	gold quality
artery	UBERON:0001637	99.95	gold quality
trigeminal ganglion	UBERON:0001675	99.95	gold quality
popliteal artery	UBERON:0002250	99.95	gold quality
decidua	UBERON:0002450	99.95	gold quality
tibial artery	UBERON:0007610	99.95	gold quality
synovial joint	UBERON:0002217	99.94	gold quality
olfactory bulb	UBERON:0002264	99.94	gold quality
calcaneal tendon	UBERON:0003701	99.94	gold quality
coronary artery	UBERON:0001621	99.93	gold quality
left coronary artery	UBERON:0001626	99.93	gold quality
lower lobe of lung	UBERON:0008949	99.91	gold quality
stromal cell of endometrium	CL:0002255	99.90	gold quality
parietal pleura	UBERON:0002400	99.90	gold quality
tendon of biceps brachii	UBERON:0008188	99.90	gold quality
right ovary	UBERON:0002118	99.89	gold quality
left ovary	UBERON:0002119	99.89	gold quality
peritoneum	UBERON:0002358	99.89	gold quality
cartilage tissue	UBERON:0002418	99.89	gold quality

Single-cell (SCXA)

Detected in 90 experiment(s), a significant marker in 62.

Experiment	Marker?	Max mean expression
E-HCAD-36	yes	17123.00
E-MTAB-7407	yes	16811.04
E-GEOD-137537	yes	14012.52
E-MTAB-8142	yes	13936.54
E-GEOD-135922	yes	12559.53
E-CURD-79	yes	10585.91
E-MTAB-9154	yes	8573.37
E-MTAB-8205	yes	8235.09
E-GEOD-134144	yes	8030.79
E-MTAB-9841	yes	7971.21
E-MTAB-10596	yes	7907.32
E-MTAB-10855	yes	7727.88
E-GEOD-124263	yes	7715.33
E-CURD-112	yes	7675.41
E-MTAB-9906	yes	7616.13

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
PLVAP	Activation

Upstream regulators (CollecTRI, top): AP1, AR, ATF4, CDK9, CTNNB1, CUX1, CXXC1, ERG, ESR1, ETV4, EZH2, FOS, FOXC1, GLI1, HDGF, HEXIM1, HIF1A, HIPK2, HMGA2, HNF4A, HOXA5, HOXA7, HSF4, IRF6, JDP2, JUN, KLF4, KLF8, LEF1, MARK1, MTA1, MYB, NFKB1, NFKB, OVOL2, PARP1, PAWR, PBX1, POLR2A, RBMS3

miRNA regulators (miRDB)

50 targeting VIM, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-1287-3P	99.63	66.93	492
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-7844-5P	99.55	68.56	1428

Literature-anchored findings (GeneRIF, showing 40)

• These findings suggest that platelet vimentin may regulate fibrinolysis in plasma and thrombi by binding platelet-derived Vn.PAI-1 complexes. (PMID:11744725)
• association with MICAL, a novel CasL interacting molecule (PMID:11827972)
• Vimentin expression correlates with the cytoplasmic localization of wild-type p53 in human primary glioblastoma. (PMID:12084347)
• Menin’s interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. (PMID:12169273)
• Results describe the asymmetric distribution of vimentin in the human sperm head. (PMID:12194205)
• expression correlated with motility of prostate carcinoma cells, poor cell differentiation, and presence of bone metastasis (PMID:12210485)
• specific interaction of the periplakin linker domain with keratin 8 and vimentin (PMID:12366696)
• The 3’ untranslated region of human vimentin mRNA binds protein complexes containing eEF-1gamma and HAX-1. (PMID:12466525)
• It is secreted by activated monocyte-derived macrophages (PMID:12483219)
• vimentin expression contributes to the invasive phenotype in androgen-independent prostate cancer but cannot confer it alone. (PMID:12727854)
• The vimentin promoter is a target of the beta-catenin/TCF pathway and strongly suggest an implication of this regulation in epithelial cell migration/invasion in breast cancer. (PMID:12750294)
• role of mitogen-activated protein kinase-activated protein kinase-2 phosphorylation in retaining assembly capacity (PMID:12761892)
• vimentin, in conjunction with low molecular weight heparan sulfate proteoglycans, contributes to the enhanced binding of human group IIA PLA2 to apoptotic T cells (PMID:12829607)
• High MW vimentin was formed after the digestion of vimentin by caspase-3 but not caspase-8. It acted as an autoantigen to form anti-vimentin autoantibody in vivo. (PMID:12906105)
• findings implicate reduced vimentin in the conversion of these tumorigenic prostate epithelial cells into slow growing, less aggressive cells (PMID:14595690)
• study of human vimentin rod 1 structure and the sequencing of assembly steps in intermediate filament formation (PMID:15231822)
• It is unlikely that ependymal vimentin is directly involved in the pathogenesis of Chiari II malformation, but may reflect a secondary upregulation due to defective expression of another gene. (PMID:15255035)
• Data suggest that the PAL-E antibody defines secretion of vimentin as a molecular distinction among endothelial cells and exposes a novel, extracellular role for vimentin in the blood vasculature. (PMID:15456890)
• examination of mutation the LNDR to LNDS motif in vimentin to examine role in epidermolysis bullosa simplex (PMID:15556930)
• Interacts with alpha2beta1-enriched focal adhesions and this association is lost after prolonged adhesion of endothelial cells to collagen. (PMID:15777792)
• Results indicate that protein kinase C epsilon-mediated phosphorylation of vimentin is a key process in integrin traffic through the cell. (PMID:16270034)
• Kidney recipients from non-heart-beating donors showed higher levels of anti-vimentin antibodies than heart-beating donors. (PMID:16298568)
• Apoptotic neutrophils express vimentin on their surface; these cells may participate in the development of autoantibodies directed against cytoskeletal proteins, a condition frequently reported in several inflammatory diseases. (PMID:16365157)
• All polyps were immunohistochemically positive for vimentin. (PMID:16487365)
• regulation of vimentin is controlled by SIP1 in breast neoplasms (PMID:16568083)
• isolated & identified vimentin as the major skeletal-muscle group A streptococcus (GAS)-binding protein; vimentin expression was up-regulated on injured skeletal-muscle cells in vitro and was expressed in muscle tissues from a patient with GAS myonecrosis (PMID:16703512)
• actin and vimentin filaments can interact directly through the tail domain of vimentin (PMID:16901892)
• Data show that the architecture of the vimentin cytoskeleton is modified by perturbation of the GTPase ARF1. (PMID:16912072)
• Increased vimentin expression was found in pseudomyxoma peritonei. (PMID:17031402)
• unit-length filaments appears to be a dynamic and a relatively loosely packed structure with a roughly even mass distribution over its cross-section (PMID:17050693)
• Vimentin is involved in binding of NKp46 to M. tuberculosis H37Ra-infected mononuclear phagocytes. (PMID:17056548)
• The regulatory protease factor Xa is able to cleave IbeA between R297 and K298 residues, and this cleavage abolishes the IbeA-vimentin interaction. (PMID:17083913)
• Vimentin filaments in cross-section exhibit predominantly a four-stranded protofibrilar organization with a right-handed supertwist with a helical pitch of about 96 nm. (PMID:17289402)
• a kinetic model for the in vitro assembly of intermediate filaments from tetrameric vimentin (PMID:17403663)
• Vimentin is a major arterial substrate for transglutaminases.Transglutaminase-mediated vimentin dimerization produces a novel unifying pathway by which vasodilatory and remodeling responses may be regulated. (PMID:17476115)
• In conclusion, ablation of vimentin expression inhibits migration and invasion of colon and breast cancer cell lines. (PMID:17585878)
• The nestin(-) vimentin(+) fibroblasts may represent a novel type of multipotent adult stem cells in human dermis. (PMID:17652163)
• ZBP-89 functions as a repressor by recruiting HDAC1 to the vimentin promoter. (PMID:17663720)
• study of vimentin protein filament structure and assembly by electron paramagnetic resonance spectroscopy of site-directed spin labels. Review. (PMID:17703067)
• The suppression of vimentin expression by ras, and the relief of this suppression by TGFbeta, occurs in a promoter-independent fashion, possibly through sequences in the first or second intron. (PMID:17719575)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	vim	ENSDARG00000010008
danio_rerio	viml	ENSDARG00000044501
mus_musculus	Vim	ENSMUSG00000026728
rattus_norvegicus	Vim	ENSRNOG00000018087

Paralogs (68): KRT33A (ENSG00000006059), KRT31 (ENSG00000094796), NEFM (ENSG00000104722), KRT23 (ENSG00000108244), KRT37 (ENSG00000108417), KRT32 (ENSG00000108759), KRT18 (ENSG00000111057), LMNB1 (ENSG00000113368), KRT36 (ENSG00000126337), KRT17 (ENSG00000128422), GFAP (ENSG00000131095), KRT34 (ENSG00000131737), KRT33B (ENSG00000131738), NES (ENSG00000132688), PRPH (ENSG00000135406), KRT85 (ENSG00000135443), KRT7 (ENSG00000135480), KRT71 (ENSG00000139648), INA (ENSG00000148798), LMNTD1 (ENSG00000152936), LMNA (ENSG00000160789), KRT84 (ENSG00000161849), KRT82 (ENSG00000161850), KRT80 (ENSG00000167767), KRT1 (ENSG00000167768), KRT24 (ENSG00000167916), KRT8 (ENSG00000170421), KRT78 (ENSG00000170423), KRT86 (ENSG00000170442), KRT75 (ENSG00000170454), KRT6C (ENSG00000170465), KRT4 (ENSG00000170477), KRT74 (ENSG00000170484), KRT72 (ENSG00000170486), KRT83 (ENSG00000170523), BFSP2 (ENSG00000170819), KRT19 (ENSG00000171345), KRT15 (ENSG00000171346), KRT38 (ENSG00000171360), KRT13 (ENSG00000171401)

Protein

Protein identifiers

Vimentin — P08670 (reviewed: P08670)

All UniProt accessions (6): A0A1B0GTT5, A0A1B0GVG8, B0YJC4, B0YJC5, P08670, V9HWE1

UniProt curated annotations — full annotation on UniProt →

Function. Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. Plays a role in cell directional movement, orientation, cell sheet organization and Golgi complex polarization at the cell migration front. Protects SCRIB from proteasomal degradation and facilitates its localization to intermediate filaments in a cell contact-mediated manner. May promote axon outgrowth and motor fiber repair via DSP-mediated recruitment to outgrowth tips. Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.

Subunit / interactions. Homomer assembled from elementary dimers. Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2, ANK2, PLEC, PRX and spectrin. Identified in a complex containing at least DSP, JUP, VIM and CDH2; the complex is more abundant following crush injury in regenerating motor neurons and may promote axon outgrowth and motor fiber repair. Interacts with BCAS3. Interacts with LGSN. Interacts with SYNM. Interacts (via rod region) with PLEC (via CH 1 domain). Interacts with PLEC isoform 1C. Interacts with STK33. Interacts with LARP6. Interacts with RAB8B. Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton. Interacts with TOR1AIP1. Interacts with DIAPH1. Interacts with EPPK1; interaction is dependent of higher-order structure of intermediate filament. Interacts with the non-receptor tyrosine kinase SRMS; the interaction leads to phosphorylation of VIM. Interacts with NOD2. Interacts (via head region) with CORO1C. Interacts with HDGF (isoform 2). Interacts with PRKCE (via phorbol-ester/DAG-type 2 domain). Interacts with BFSP2. Interacts with PPL. Interacts (via rod domain) with PKP1. Interacts with PKP2. Interacts with SCRIB (via PDZ domains); the interaction protects SCRIB from proteasomal degradation and facilitates SCRIB localization to intermediate filaments, the interaction is reduced by cell contact inhibition. (Microbial infection) Interacts with HCV core protein. (Microbial infection) Interacts with Chandipura virus glycoprotein; this interaction might facilitate the binding of the virus to the cells.

Subcellular location. Cytoplasm. Cytoskeleton. Nucleus matrix. Cell membrane. Cell projection. Axon.

Tissue specificity. Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt’s lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.

Post-translational modifications. Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin. One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. Phosphorylated on tyrosine residues by SRMS. O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status. S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.

Disease relevance. Cataract 30, multiple types (CTRCT30) [MIM:116300] An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The central alpha-helical coiled-coil IF rod domain mediates elementary homodimerization. The [IL]-x-C-x-x-[DE] motif is a proposed target motif for cysteine S-nitrosylation mediated by the iNOS-S100A8/A9 transnitrosylase complex.

Induction. Up-regulated by muramyl-dipeptide and lipopolysaccharide.

Similarity. Belongs to the intermediate filament family.

RefSeq proteins (1): NP_003371* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006821	Intermed_filament_DNA-bd	Domain
IPR018039	IF_conserved	Conserved_site
IPR039008	IF_rod_dom	Domain
IPR050405	Intermediate_filament	Family

Pfam: PF00038, PF04732

UniProt features (106 total): modified residue 56, cross-link 12, sequence conflict 9, region of interest 8, helix 4, coiled-coil region 3, glycosylation site 3, compositionally biased region 2, sequence variant 2, initiator methionine 1, chain 1, strand 1, turn 1, short sequence motif 1, site 1, domain 1

Structure

Experimental structures (PDB)

26 structures.

PDB	Method	Resolution (Å)
1GK7	X-RAY DIFFRACTION	1.4
4YPC	X-RAY DIFFRACTION	1.44
4MD5	X-RAY DIFFRACTION	1.65
3SWK	X-RAY DIFFRACTION	1.7
4MDJ	X-RAY DIFFRACTION	1.7
3G1E	X-RAY DIFFRACTION	1.83
1GK6	X-RAY DIFFRACTION	1.9
6ATF	X-RAY DIFFRACTION	1.9
6ATI	X-RAY DIFFRACTION	1.98
4MDI	X-RAY DIFFRACTION	2
4YV3	X-RAY DIFFRACTION	2
6YXK	X-RAY DIFFRACTION	2
4MD0	X-RAY DIFFRACTION	2.19
5WHF	X-RAY DIFFRACTION	2.25
1GK4	X-RAY DIFFRACTION	2.3
3TRT	X-RAY DIFFRACTION	2.3
4MCY	X-RAY DIFFRACTION	2.3
6BIR	X-RAY DIFFRACTION	2.3
4MCZ	X-RAY DIFFRACTION	2.41
3S4R	X-RAY DIFFRACTION	2.45
3SSU	X-RAY DIFFRACTION	2.6
8TRR	X-RAY DIFFRACTION	2.65
3KLT	X-RAY DIFFRACTION	2.7
8TRQ	X-RAY DIFFRACTION	2.75
3UF1	X-RAY DIFFRACTION	2.81
8RVE	ELECTRON MICROSCOPY	7.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P08670-F1	78.05	0.52

Antibody-complex structures (SAbDab): 1 — 6YXK

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 351 (stutter)

Post-translational modifications (68): 2, 5, 7, 8, 9, 10, 20, 25, 26, 34, 39, 42, 47, 49, 51, 53, 55, 56, 61, 66 …

Glycosylation sites (3): 7, 33, 34

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins
R-HSA-390522	Striated Muscle Contraction
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-9013422	RHOBTB1 GTPase cycle
R-HSA-9613829	Chaperone Mediated Autophagy
R-HSA-9615710	Late endosomal microautophagy
R-HSA-9646399	Aggrephagy
R-HSA-9918481	Dengue Virus-Host Interactions
R-HSA-9918487	Dengue Virus Genome Translation and Replication
R-HSA-9927432	Developmental Lineage of Mammary Gland Myoepithelial Cells

MSigDB gene sets: 564 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, TSUNODA_CISPLATIN_RESISTANCE_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_LENS_FIBER_CELL_DIFFERENTIATION, GOBP_EPITHELIUM_DEVELOPMENT, IIZUKA_LIVER_CANCER_EARLY_RECURRENCE, GOBP_INTERMEDIATE_FILAMENT_BASED_PROCESS, DORSAM_HOXA9_TARGETS_UP, YAGI_AML_WITH_INV_16_TRANSLOCATION, HARRIS_HYPOXIA, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GOBP_INTERMEDIATE_FILAMENT_ORGANIZATION, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID

GO Biological Process (13): positive regulation of gene expression (GO:0010628), negative regulation of neuron projection development (GO:0010977), astrocyte development (GO:0014002), neuron projection development (GO:0031175), positive regulation of collagen biosynthetic process (GO:0032967), regulation of mRNA stability (GO:0043488), intermediate filament organization (GO:0045109), Bergmann glial cell differentiation (GO:0060020), lens fiber cell development (GO:0070307), cellular response to lipopolysaccharide (GO:0071222), cellular response to muramyl dipeptide (GO:0071225), cellular response to type II interferon (GO:0071346), intermediate filament-based process (GO:0045103)

GO Molecular Function (10): double-stranded RNA binding (GO:0003725), structural constituent of cytoskeleton (GO:0005200), structural constituent of eye lens (GO:0005212), protein domain specific binding (GO:0019904), identical protein binding (GO:0042802), molecular adaptor activity (GO:0060090), scaffold protein binding (GO:0097110), keratin filament binding (GO:1990254), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (18): cytoplasm (GO:0005737), peroxisome (GO:0005777), microtubule organizing center (GO:0005815), cytosol (GO:0005829), cytoskeleton (GO:0005856), intermediate filament (GO:0005882), plasma membrane (GO:0005886), focal adhesion (GO:0005925), nuclear matrix (GO:0016363), axon (GO:0030424), cell leading edge (GO:0031252), intermediate filament cytoskeleton (GO:0045111), phagocytic vesicle (GO:0045335), extracellular exosome (GO:0070062), nucleus (GO:0005634), membrane (GO:0016020), cell projection (GO:0042995), neuron projection (GO:0043005)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Autophagy	2
Dengue Virus Infection	2
Apoptotic cleavage of cellular proteins	1
Muscle contraction	1
Signaling by Interleukins	1
RHOBTB GTPase Cycle	1
Selective autophagy	1
Developmental Lineages of the Mammary Gland	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	7
protein binding	3
astrocyte differentiation	2
cellular response to oxygen-containing compound	2
structural molecule activity	2
cytoskeleton	2
binding	2
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
regulation of neuron projection development	1
neuron projection development	1
negative regulation of cell projection organization	1
glial cell development	1
neuron development	1
plasma membrane bounded cell projection organization	1
positive regulation of biosynthetic process	1
positive regulation of collagen metabolic process	1
collagen biosynthetic process	1
regulation of collagen biosynthetic process	1
regulation of RNA stability	1
regulation of mRNA catabolic process	1
intermediate filament cytoskeleton organization	1
supramolecular fiber organization	1
epithelial cell development	1
lens fiber cell differentiation	1
response to lipopolysaccharide	1
cellular response to molecule of bacterial origin	1
cellular response to lipid	1
response to muramyl dipeptide	1
cellular response to nitrogen compound	1
response to type II interferon	1
cellular response to cytokine stimulus	1
cellular process	1
RNA binding	1
cytoskeleton organization	1
molecular_function	1
intermediate filament binding	1
nucleic acid binding	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

4902 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
VIM	ZEB1	P37275	913
VIM	CDH1	P12830	892
VIM	ZEB2	O60315	889
VIM	SNAI2	O43623	881
VIM	UBAC1	Q9BSL1	874
VIM	SNAI1	O95863	851
VIM	TWIST1	Q15672	818
VIM	PLEC	Q15149	807
VIM	FN1	P02751	795
VIM	CDH2	P19022	779
VIM	LGALS1	P09382	763
VIM	ACTA2	P03996	756
VIM	VCP	P55072	753
VIM	GAPDH	P00354	752
VIM	COL1A1	P02452	750
VIM	CD44	P16070	750

IntAct

803 interactions, top by confidence:

A	B	Type	Score
VIM	VIM	psi-mi:“MI:0407”(direct interaction)	0.910
VIM	VIM	psi-mi:“MI:2364”(proximity)	0.910
VIM	VIM	psi-mi:“MI:0915”(physical association)	0.910
NOD2	VIM	psi-mi:“MI:0915”(physical association)	0.850
NOD2	VIM	psi-mi:“MI:0403”(colocalization)	0.850
VIM	NEFL	psi-mi:“MI:0914”(association)	0.840
CAPN1	CAPNS1	psi-mi:“MI:0914”(association)	0.840
VIM	KRT20	psi-mi:“MI:0915”(physical association)	0.830
KRT20	VIM	psi-mi:“MI:0915”(physical association)	0.830
DES	VIM	psi-mi:“MI:0915”(physical association)	0.820
VIM	NES	psi-mi:“MI:0915”(physical association)	0.800
VIM	TXLNB	psi-mi:“MI:0915”(physical association)	0.720
VIM	PNMA5	psi-mi:“MI:0915”(physical association)	0.720
TXLNB	VIM	psi-mi:“MI:0915”(physical association)	0.720
PNMA5	VIM	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (1109): VIM (Affinity Capture-MS), VIM (Affinity Capture-Western), VIM (Reconstituted Complex), VIM (Affinity Capture-MS), VIM (Affinity Capture-MS), VIM (Affinity Capture-MS), VIM (Two-hybrid), VIM (Two-hybrid), KRT20 (Two-hybrid), PNMA5 (Two-hybrid), CWF19L2 (Two-hybrid), TXLNB (Two-hybrid), VIM (Affinity Capture-MS), VIM (Affinity Capture-MS), VIM (Affinity Capture-MS)

ESM2 similar proteins: A0A125S9M4, A0A125S9M5, A0A125S9M6, A0A8C0N8E3, O62654, P02540, P02541, P02542, P02543, P02544, P02545, P08552, P08670, P09654, P10999, P11048, P14732, P16275, P17661, P20152, P21910, P22488, P23239, P23729, P24789, P24790, P31000, P31001, P31393, P35617, P48616, P48670, P48673, P48674, P48675, P48676, P48678, P48679, P84198, Q03427

Diamond homologs: A0A8C0N8E3, A5A6M8, A5A6N0, A6QQJ3, B4F721, O62654, O77788, O93532, O95678, P02538, P02540, P02541, P02542, P02543, P02544, P02547, P02548, P03995, P04259, P05786, P05787, P07196, P07197, P08551, P08552, P08553, P08670, P08729, P08776, P09654, P11679, P12035, P12036, P12839, P13647, P14136, P15331, P16053, P16878, P16884

SIGNOR signaling

49 interactions.

A	Effect	B	Mechanism
PAK1	unknown	VIM	phosphorylation
PLK1	up-regulates	VIM	phosphorylation
AKT	“up-regulates quantity by stabilization”	VIM	phosphorylation
AKT1	“up-regulates quantity by stabilization”	VIM	phosphorylation
ERG	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
ETV4	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
TOR1AIP1	“up-regulates activity”	VIM	binding
RNF208	“down-regulates quantity by destabilization”	VIM	ubiquitination
PRKCZ	“up-regulates activity”	VIM	phosphorylation
PRKCI	“up-regulates activity”	VIM	phosphorylation
VIM	“up-regulates activity”	LARP6	binding
hsa-mir-494-3p	“down-regulates quantity by repression”	VIM	“post transcriptional regulation”
hsa-miR-30a-3p	“down-regulates quantity by repression”	VIM	“post transcriptional regulation”
hsa-miR-148a-3p	“down-regulates quantity by repression”	VIM	“post transcriptional regulation”
CDK5	“up-regulates activity”	VIM	phosphorylation
PRKCB	“up-regulates quantity”	VIM	phosphorylation
TWIST1	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
VIM	up-regulates	Epithelial-mesenchymal_transition
ZEB1	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
SNAI1	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
SNAI2	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
LEF1	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
TCF7	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
CDK1	down-regulates	VIM	phosphorylation
AURKB	down-regulates	VIM	phosphorylation
PRKCA	“down-regulates quantity by destabilization”	VIM	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 158 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
EML4 and NUDC in mitotic spindle formation	8	7.1×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
microtubule-based movement	6	12.2×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

135 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	67
Likely benign	28
Benign	25

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
692107	NM_003380.5(VIM):c.1160T>C (p.Leu387Pro)	Likely pathogenic

SpliceAI

911 predictions. Top by Δscore:

Variant	Effect	Δscore
10:17229981:GAGAA:G	donor_gain	1.0000
10:17229983:G:GT	donor_gain	1.0000
10:17229983:GAA:G	donor_gain	1.0000
10:17229986:G:GG	donor_gain	1.0000
10:17233575:T:A	acceptor_gain	1.0000
10:17233580:A:AG	acceptor_gain	1.0000
10:17233581:A:G	acceptor_gain	1.0000
10:17233582:AATAG:A	acceptor_gain	1.0000
10:17233583:ATAG:A	acceptor_gain	1.0000
10:17233584:TA:T	acceptor_loss	1.0000
10:17233585:A:AG	acceptor_gain	1.0000
10:17233585:AG:A	acceptor_gain	1.0000
10:17233585:AGGAT:A	acceptor_gain	1.0000
10:17233586:G:GA	acceptor_gain	1.0000
10:17233586:GG:G	acceptor_gain	1.0000
10:17233586:GGA:G	acceptor_gain	1.0000
10:17233586:GGAT:G	acceptor_gain	1.0000
10:17233586:GGATG:G	acceptor_gain	1.0000
10:17233680:GAG:G	donor_gain	1.0000
10:17233683:G:GG	donor_gain	1.0000
10:17233683:GTTA:G	donor_loss	1.0000
10:17233765:T:TA	acceptor_gain	1.0000
10:17233768:A:AG	acceptor_gain	1.0000
10:17233768:AG:A	acceptor_gain	1.0000
10:17233769:G:A	acceptor_gain	1.0000
10:17233769:G:GA	acceptor_gain	1.0000
10:17233769:GGA:G	acceptor_gain	1.0000
10:17233769:GGAA:G	acceptor_gain	1.0000
10:17233769:GGAAA:G	acceptor_gain	1.0000
10:17233905:G:GT	donor_gain	1.0000

AlphaMissense

3061 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:17229742:T:C	L107P	1.000
10:17229751:T:A	L110Q	1.000
10:17229751:T:C	L110P	1.000
10:17229753:A:G	N111D	1.000
10:17229754:A:T	N111I	1.000
10:17229755:T:A	N111K	1.000
10:17229755:T:G	N111K	1.000
10:17229760:G:C	R113P	1.000
10:17229763:T:C	F114S	1.000
10:17229763:T:G	F114C	1.000
10:17229766:C:A	A115D	1.000
10:17229775:T:A	I118N	1.000
10:17229787:G:C	R122P	1.000
10:17229793:T:C	L124P	1.000
10:17229802:A:C	Q127P	1.000
10:17229814:T:C	L131P	1.000
10:17229892:T:C	L157P	1.000
10:17229946:G:C	R175P	1.000
10:17233621:T:C	L220P	1.000
10:17235299:T:C	L380P	1.000
10:17235311:A:C	Q384P	1.000
10:17235317:T:C	L386P	1.000
10:17235320:T:A	L387H	1.000
10:17235320:T:C	L387P	1.000
10:17235328:A:G	K390E	1.000
10:17235330:G:C	K390N	1.000
10:17235330:G:T	K390N	1.000
10:17235334:G:C	A392P	1.000
10:17235337:C:T	L393F	1.000
10:17235338:T:A	L393H	1.000

dbSNP variants (sampled 300 via entrez): RS1000052726 (10:17228351 C>A,T), RS1000104769 (10:17228140 T>C), RS1000124528 (10:17228524 G>A,C), RS1001006043 (10:17232991 A>G), RS1001045982 (10:17226871 T>C), RS1001057234 (10:17232997 G>A,C), RS1001456740 (10:17232561 G>A), RS1001870717 (10:17237422 C>A,T), RS1001879216 (10:17237170 A>G), RS1001879572 (10:17226923 G>A), RS1001941060 (10:17232473 A>C), RS1001947317 (10:17228322 G>A,C,T), RS1002062743 (10:17231140 G>A), RS1002791003 (10:17237398 G>A), RS1002872537 (10:17236026 G>A,C,T)

Disease associations

OMIM: gene MIM:193060 | disease phenotypes: MIM:116300, MIM:261100

GenCC curated gene-disease

Disease	Classification	Inheritance
cataract	Definitive	Autosomal dominant
cataract 30	Strong	Autosomal dominant
pulverulent cataract	Supportive	Autosomal dominant

Mondo (4): cataract 30 (MONDO:0007286), Imerslund-Grasbeck syndrome (MONDO:0009853), pulverulent cataract (MONDO:0011430), cataract (MONDO:0005129)

Orphanet (4): Early onset non-syndromic cataract (Orphanet:91492), Pulverulent cataract (Orphanet:98984), Early-onset partial cataract (Orphanet:98992), Imerslund-Gräsbeck syndrome (Orphanet:35858)

HPO phenotypes

5 total (5 of 5 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001115	Posterior polar cataract
HP:0003577	Congenital onset
HP:0007657	Diffuse nuclear cataract
HP:0010693	Pulverulent cataract

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002221_72	Cholesterol, total	3.000000e-11
GCST004235_38	Total cholesterol levels	5.000000e-11
GCST010242_453	HDL cholesterol levels	6.000000e-11
GCST010244_172	Triglyceride levels	2.000000e-08
GCST90002397_704	Mean spheric corpuscular volume	8.000000e-14
GCST90011899_33	Aspartate aminotransferase levels	3.000000e-21

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004574	total cholesterol measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004530	triglyceride measurement
EFO:0004736	aspartate aminotransferase measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D002386	Cataract	C11.510.245
C565133	Cataract, Coppock-Like (supp.)
C566157	Cataract, Nuclear Diffuse Nonprogressive (supp.)
C538556	Imerslund-Grasbeck syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712854 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.19	Kd	640.2	nM	CHEMBL3752910
6.00	Kd	1000	nM	CHEMBL5412999
6.00	Kd	1005	nM	CHEMBL5653589
5.99	ED50	1033	nM	CHEMBL3752910
5.79	ED50	1622	nM	CHEMBL5653589

PubChem BioAssay actives

3 with measured affinity, of 30 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149765: Binding affinity to human VIM incubated for 45 mins by Kinobead based pull down assay	kd	0.6402	uM
(2R)-6-amino-N-[(2R)-1-[[6-amino-5-[[(2R)-2-[[(2R)-6-amino-2-[[2-[[2-[[2-[[2-[4-aminobutyl-[2-[4-aminobutyl-[2-[[2-(4-benzoylanilino)acetyl]-(2-methylpropyl)amino]acetyl]amino]acetyl]amino]acetyl]-(2-methylpropyl)amino]acetyl]-(1,3-benzodioxol-5-ylmethyl)amino]acetyl]-(2-methoxyethyl)amino]acetyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-6-oxohexyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]-2-[[2-[[2-[[2-[[2-[4-aminobutyl-[2-[4-aminobutyl-[2-[[2-(4-benzoylanilino)acetyl]-(2-methylpropyl)amino]acetyl]amino]acetyl]amino]acetyl]-(2-methylpropyl)amino]acetyl]-(1,3-benzodioxol-5-ylmethyl)amino]acetyl]-(2-methoxyethyl)amino]acetyl]amino]hexanamide	2005096: Binding affinity to his-tagged recombinant Vimentin (unknown origin) assessed as dissociation constant by ELISA analysis	kd	1.0000	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149765: Binding affinity to human VIM incubated for 45 mins by Kinobead based pull down assay	kd	1.0047	uM

CTD chemical–gene interactions

396 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, increases reaction, decreases reaction, increases abundance, decreases expression (+3 more)	30
bisphenol A	affects cotreatment, decreases expression, increases expression, increases reaction, affects reaction (+1 more)	15
Cadmium Chloride	affects cotreatment, affects binding, decreases reaction, increases reaction, increases cleavage (+9 more)	14
Tretinoin	decreases expression, increases reaction, affects cotreatment, increases expression	12
Particulate Matter	decreases expression, increases abundance, increases expression, decreases reaction, affects reaction (+1 more)	12
Resveratrol	affects cotreatment, decreases expression, affects secretion, decreases reaction, increases expression	9
Arsenic	increases expression, increases reaction, decreases reaction, increases ubiquitination, increases abundance (+4 more)	9
Benzo(a)pyrene	decreases expression, increases methylation, affects reaction, decreases reaction, increases expression (+2 more)	8
Estradiol	decreases reaction, increases expression, affects cotreatment, decreases expression, increases reaction (+1 more)	8
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases reaction, increases abundance, increases expression, affects cotreatment	7
bisphenol S	affects cotreatment, decreases methylation, increases expression, decreases expression, affects reaction	7
Arsenic Trioxide	increases reaction, increases expression, affects reaction, decreases reaction, decreases expression	7
Cadmium	increases palmitoylation, increases expression, decreases expression, decreases reaction, increases abundance	7
Silicon Dioxide	affects secretion, increases secretion, affects reaction, decreases reaction, increases expression (+1 more)	7
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	affects binding, decreases reaction, increases reaction, increases secretion, increases abundance (+4 more)	6
arsenite	increases expression, affects binding, decreases expression, increases oxidation, decreases reaction (+3 more)	5
Fulvestrant	decreases methylation, affects cotreatment, decreases reaction, increases expression	5
Acetylcysteine	increases expression, increases abundance, decreases expression, decreases reaction	5
Cisplatin	increases reaction, increases expression, decreases reaction, decreases expression	5
Niclosamide	decreases reaction, increases expression, decreases response to substance, increases phosphorylation, decreases expression	5
Tobacco Smoke Pollution	decreases reaction, increases expression, increases reaction, affects expression, decreases expression	5
Valproic Acid	decreases expression, increases expression	5
cobaltous chloride	decreases reaction, increases expression, increases reaction	4
SB 203580	increases expression, increases phosphorylation, increases abundance, decreases reaction	4
U 0126	decreases reaction, increases expression, increases abundance, increases reaction, increases phosphorylation	4
Copper	affects cotreatment, decreases expression, affects binding, increases cleavage	4
Doxorubicin	decreases phosphorylation, increases expression, increases response to substance, affects expression, affects cotreatment (+1 more)	4
Endosulfan	increases expression, decreases reaction	4
Glucose	affects cotreatment, increases expression, increases secretion, increases reaction	4
Plant Extracts	increases expression, decreases expression, decreases reaction	4

ChEMBL screening assays

18 unique, capped per target: 18 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4270856	Binding	Binding affinity to vimentin in human Hela cells lysates assessed as protein enrichment by measuring normalized heavy/light ratio at by nano-LC-ESIMS/MS analysis	Determination of Gymnemic Acid I as a Protein Biosynthesis Inhibitor Using Chemical Proteomics. — J Nat Prod

Cellosaurus cell lines

7 cell lines: 7 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2L2	Abcam HeLa VIM KO	Cancer cell line	Female
CVCL_B8RP	Abcam HCT 116 VIM KO	Cancer cell line	Male
CVCL_B9U4	Abcam A-549 VIM KO	Cancer cell line	Male
CVCL_D1UW	Abcam U-87MG VIM KO	Cancer cell line	Male
CVCL_E0SW	Ubigene HeLa VIM KO	Cancer cell line	Female
CVCL_TX43	HAP1 VIM (-) 1	Cancer cell line	Male
CVCL_TX44	HAP1 VIM (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00273221	PHASE4	UNKNOWN	Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial
NCT00312299	PHASE4	COMPLETED	Posterior Capsule Opacification Study
NCT00345046	PHASE4	COMPLETED	A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00347243	PHASE4	COMPLETED	Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical Intraocular Lenses
NCT00347503	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00348244	PHASE4	COMPLETED	Ketorolac vs. Steroid in the Prevention of CME
NCT00348270	PHASE4	COMPLETED	Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses
NCT00348582	PHASE4	COMPLETED	Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
NCT00348621	PHASE4	COMPLETED	A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
NCT00349583	PHASE4	COMPLETED	Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation
NCT00355446	PHASE4	COMPLETED	Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.
NCT00386438	PHASE4	COMPLETED	Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification
NCT00392275	PHASE4	COMPLETED	Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs
NCT00428363	PHASE4	COMPLETED	Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification
NCT00449267	PHASE4	COMPLETED	Aurolab Hydrophobic Foldable Intraocular Lens Study
NCT00459303	PHASE4	COMPLETED	Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof
NCT00469690	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects
NCT00576485	PHASE4	COMPLETED	Spherical Aberration and Contrast Sensitivity in IOLs
NCT00612729	PHASE4	COMPLETED	Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.
NCT00612781	PHASE4	COMPLETED	Yellow Versus White Study
NCT00630019	PHASE4	COMPLETED	Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
NCT00673803	PHASE4	COMPLETED	Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification
NCT00684138	PHASE4	COMPLETED	ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
NCT00698724	PHASE4	COMPLETED	Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
NCT00710905	PHASE4	TERMINATED	Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3
NCT00710931	PHASE4	COMPLETED	Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1
NCT00711347	PHASE4	COMPLETED	Intraoperative Floppy Iris Syndrome
NCT00712244	PHASE4	COMPLETED	DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00719732	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3
NCT00721253	PHASE4	COMPLETED	Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA
NCT00731640	PHASE4	COMPLETED	Contralateral ReSTOR / Monofocal or Phakic Eye
NCT00732030	PHASE4	COMPLETED	Low Cylinder Toric
NCT00758199	PHASE4	COMPLETED	Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
NCT00760058	PHASE4	WITHDRAWN	Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL
NCT00760487	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens
NCT00761488	PHASE4	WITHDRAWN	Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric
NCT00763360	PHASE4	COMPLETED	To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
NCT00786370	PHASE4	COMPLETED	Dexmedetomidine vs. Propofol for Cataract Surgery
NCT00786565	PHASE4	COMPLETED	Clinical Evaluation of a New Aspheric Intraocular Lens.